Explorer

US Tariffs Pose Minimal Threat To Indian Pharma, Says Citi; Details Here

Currently, India imposes a 10 per cent tariff on pharmaceutical imports from the US, while the US does not levy any tariff on pharmaceutical imports from India

Global brokerage firm Citi said on Tuesday there is a low likelihood of the US imposing tariffs on Indian pharmaceuticals, despite ongoing discussions around the issue. The brokerage firm analysed the potential effects of a 10 per cent tariff on Indian pharmaceutical companies, particularly those with significant exposure to the US generics market.

Currently, India imposes a 10 per cent tariff on pharmaceutical imports from the US, while the US does not levy any tariff on pharmaceutical imports from India.

According to Citi's analysis, some big companies could face a potential EBITDA (earnings before interest, taxes, depreciation, and amortisation) hit of 9-12 per cent.

However, if part of the tariff is passed on to US buyers, the impact could reduce to around 5-6 per cent, though passing the full cost on to buyers is seen as challenging.

Citi also noted that companies with less exposure to the US generics market would be the least affected by potential tariffs.

These companies have diversified portfolios and lower reliance on the US generics market, making them Citi's preferred picks in the Indian pharmaceutical sector.

The report highlighted that in case of tariffs, there are factors like competition, industry fragmentation, and the influence of buying consortiums that might prevent the full pass-through of the tariff to US buyers.

Additionally, products facing competition from US manufacturers or those from non-tariff countries may not see any pass-through at all.

Despite these discussions, Citi believes that the probability of tariffs being imposed on Indian generics is low.

The firm pointed out that the US relies heavily on Indian generics due to the limited manufacturing of generics within the US itself.

Imposing tariffs could lead to drug shortages in the US if Indian suppliers were to exit the market. Citi's report suggests that while the imposition of tariffs remains unlikely, the impact on Indian pharmaceutical companies would depend on their exposure to the US generics market.

Meanwhile, US President Donald Trump has also announced a 25 per cent tariff on auto imports into the US, to be effective from April 3.

(This report has been published as part of the auto-generated syndicate wire feed. Apart from the headline, no editing has been done in the copy by ABP Live.)

Top Headlines

D-Street Bull Run: Sensex Jumps Over 890 Points, Nifty Tests 26K
D-Street Bull Run: Sensex Jumps Over 890 Points, Nifty Tests 26K
Anthropic's Trading Debut To Test Investor Appetite For AI
Anthropic's Trading Debut To Test Investor Appetite For AI
Retired Employees May Soon Get Monthly PF Payouts: What EPFO's New Plan Means
Retired Employees May Soon Get Monthly PF Payouts: What EPFO's New Plan Means
Stock Markets Jump As Sensex Soars Over 900 Points, Nifty Tests 25K
Stock Markets Jump As Sensex Soars Over 900 Points, Nifty Tests 25K

Videos

Rajasthan Panchayat Polls: Congress Wins Big, BJP Faces Setback in CM Bhajanlal Sharma's Stronghold!
UP Politics: Asaduddin Owaisi Meets Chandrashekhar Azad Over 2027 Poll Strategy After Saharanpur Mosque Row
Uttar Pradesh News: CM Yogi Performs Last Rites of Mother Savitri Devi in Haridwar, Gives Final Farewell
Uttar Pradesh News: Emotional CM Yogi Bids Final Farewell to Mother, Haridwar Cremation Ceremony Continues
Uttar Pradesh News: CM Yogi Adityanath Carries Mother's Bier as Last Rites Held in Haridwar

Photo Gallery

25°C
New Delhi
Rain: 100mm
Humidity: 97%
Wind: WNW 47km/h
See Today's Weather
powered by
Accu Weather
Embed widget